Drug intelligence / Profile preview

IDP-120 Component A

Development stage: Unknown
Lead developer: Valeant Pharmaceuticals
Administration: Topical

Overview

IDP-120 Component A is an investigational drug developed by Bausch Health Americas, Inc. and Valeant Pharmaceuticals. It is described as a single active ingredient, a "Monad of Component A", and is a component of the combination product IDP-120 Gel. It is being studied for the treatment of acne vulgaris, with clinical trials reaching Phase 2. The drug is formulated as a gel for once-daily topical application.

Beyond the preview

Go deeper on IDP-120 Component A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-120 Component A.

Explore the full profile